ReviewCardiac failure review2020
Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition.
Review in Cardiac failure review, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
- The Interplay of Comorbidities in Chronic Heart Failure: Challenges and Solutions.Current cardiology reviews · 2024Review
- Heart failure with improved ejection fraction: patient characteristics, clinical outcomes and predictors for improvement.Frontiers in cardiovascular medicine · 2024Article
- Heart failure with recovered ejection fraction and the utility of defibrillator therapy: a review.ESC heart failure · 2022Review
- Angiotensin-Converting Enzyme Inhibitor Therapy Effects in Patients With Heart Failure With Preserved and Mid-Range Ejection Fraction.Cardiology research · 2021Article
- Beta-blockers are associated with reverse remodeling in patients with dilated cardiomyopathy and mid-range ejection fraction.American heart journal plus : cardiology research and practice · 2021Article
- Tricuspid Regurgitation in Left Ventricular Systolic Dysfunction: Marker or Target?Frontiers in cardiovascular medicine · 2021Review
- Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition.Cardiac failure review · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent definition of an intermediate clinical phenotype of heart failure (HF) based on an ejection fraction (EF) of between 40% and 49%, namely HF with mid-range EF (HFmrEF), has fuelled investigations into the clinical profile and prognosis of this patient group. HFmrEF shares common clinical features with other HF phenotypes, such as a high prevalence of ischaemic aetiology, as in HF with reduced EF (HFrEF), or hypertension and diabetes, as in HF with preserved EF (HFpEF), and benefits from the cornerstone drugs indicated for HFrEF. Among the HF phenotypes, HFmrEF is characterised by the highest rate of transition to either recovery or worsening of the severe systolic dysfunction profile that is the target of disease-modifying therapies, with opposite prognostic implications. This article focuses on the epidemiology, clinical characteristics and therapeutic approaches for HFmrEF, and discusses the major determinants of transition to HFpEF or HFrEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.